Increased red blood cell alloimmunization rates in transfused aplastic anemia and myelofibrosis patients.

Autor: Sotolongo G; Department of Pathology, Duke University Hospital, Durham, North Carolina, USA., Poisson JL; Department of Pathology, Duke University Hospital, Durham, North Carolina, USA.
Jazyk: angličtina
Zdroj: Transfusion [Transfusion] 2023 Oct; Vol. 63 (10), pp. 1803-1808. Date of Electronic Publication: 2023 Aug 30.
DOI: 10.1111/trf.17529
Abstrakt: Background: Red blood cell (RBC) alloimmunization (AI) is a well-known complication of RBC transfusions, which results in the formation of alloantibodies to non-self antigens on donor RBCs, putting patients at risk of transfusion-related complications. The rate of AI with RBC transfusions in the general hospitalized population is estimated to be 2%-3%. However, some patients who are deemed "transfusion-dependent" require regular transfusions of blood products due to persistently low cell counts, putting them at even greater risk of RBC AI and increased morbidity. However, few studies currently exist investigating RBC AI in some transfusion-dependent patient populations, e.g., aplastic anemia (AA) and myelofibrosis (MF).
Study Design and Methods: We conducted a 5-year retrospective review to investigate the prevalence of RBC AI, alloantibody incidence, and the number of RBC transfusions in AA and MF patients, who received RBC transfusions within our hospital system.
Results: During the study period, 64 AA and 93 MF patients received 1301 and 2766 RBC transfusions, respectively. Compared to the RBC AI rate in the generalized hospitalized patient population (1%-2%), patients with AA and MF had an increased rate of RBC AI incidence rate at 14.1% and 12.9%, respectively. Furthermore, patients with primary MF demonstrated an isolated increased RBC AI incidence rate of 13.3%. The most common alloantibodies produced were anti-E and anti-K.
Discussion: Within our institution, patients with AA and MF had increased incidence rates of RBC AI compared to the general hospitalized patient population and may benefit from an antigen-matched protocol to minimize AI-related complications.
(© 2023 AABB.)
Databáze: MEDLINE
Externí odkaz: